This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Biotech Stock Outlook: Short-Term Pricing Pain to Prevail
by Zacks Equity Research
Decline in sales of high-profile drugs, pipeline setbacks and competitive pressure are likely to adversely impact the overall performance of the biotech sector in the short term.
Merck's Keytruda Gets Priority Review in Difficult Lung Cancer
by Zacks Equity Research
Merck's (MRK) sBLA looking to expand the label of Keytruda for first-line treatment of metastatic squamous NSCLC gets FDA's priority review. The decision is expected on Oct 30.
Should Value Investors Consider Amgen (AMGN) Stock Now?
by Zacks Equity Research
Let's see if Amgen Inc. (AMGN) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
4 Drug and Biotech Stocks Awaiting FDA Decisions in July
by Kinjel Shah
In the first six months of the year, the FDA grants approval to 17 new treatments.
4 Biotech Stocks to Bet on in the Second Half of 2018
by Ekta Bagri
While the first half did not turn out to be great for the biotech sector, the second half is expected to be much better. Here, we list four biotechs poised for a good run.
Mylan, Lupin Collaborate for the Proposed Biosimilar Enbrel
by Zacks Equity Research
Mylan (MYL) enters a partnership with Lupin Limited to commercialize a biosimilar of blockbuster drug Enbrel on approval.
Amgen Announces Top-Line Data From Remicade Biosimilar Study
by Zacks Equity Research
Amgen (AMGN) presents top-line results from a late-stage study evaluating its biosimilar version of Remicade. Data shows that there was no clinically meaningful difference between the two products.
5 Cheap Large Cap Stocks to Buy Now
by Tracey Ryniec
The tide has turned and the large caps are now under performing. Value investors should take a look.
AMGN or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMGN vs. ILMN: Which Stock Is the Better Value Option?
Has Amgen (AMGN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (AMGN) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Facebook, Amgen, Abbott, Coca-Cola and 3M
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Amgen, Abbott, Coca-Cola and 3M
Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod
by Zacks Equity Research
The biotech sector was in the news with a few hits and misses. Gilead's Biktarvy got approval in Europe while Puma Biotechology is also closer to breast cancer drug approval in Europe.
Merck's Keytruda Under FDA Review for Advanced Melanoma
by Zacks Equity Research
Merck (MRK) announces acceptance of its sBLA for Keytruda by the FDA for the treatment of patients with high-risk stage III melanoma.
Top Stock Reports for Facebook, Amgen & Abbott
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Amgen (AMGN), and Abbott (ABT).
Amgen's Repatha Reduces Bad Cholestrol in Type II Diabetes
by Zacks Equity Research
Amgen's (AMGN) Repatha significantly reduces LDL-C and non-HDL-C in patients with type II diabetes and hypercholesterolemia or mixed dyslipidemia.
Roche's (RHHBY) Study on Tecentriq for Lung Cancer Positive
by Zacks Equity Research
Roche's (RHHBY) phase III study on immuno-oncology drug, Tecentriq, for the treatment of small cell lung cancer meet its co-primary endpoints.
Merck (MRK) Stock Up So Far This Year on Keytruda Strength
by Zacks Equity Research
Merck's shares are up 8.4% this year driven by strong performance and positive regulatory updates related to its PD-1 inhibitor, Keytruda.
Amgen Gets EU Nod to Add Survival Data on Blincyto's Label
by Zacks Equity Research
Amgen (AMGN) gets approval from the European Commission to add overall survival (OS) data from the TOWER study on the label of its leukemia drug, Blincyto.
Biotech Stock Roundup: SRPT & SLDB Soar on Positive Data, ANIK & ZIOP Crash
by Zacks Equity Research
The biotech sector showed volatility with a few companies gaining on positive data readouts while a few plunging on dismal results.
Teva to Discontinue a Fremanezumab Study on Cluster Headache
by Zacks Equity Research
Teva decides to halt a phase III study, evaluating fremanezumab for the treatment of chronic cluster headache, following an interim analysis, which anticipates that the study is unlikely to meet its endpoint.
Roche Announces Positive Data on Gazyva and MS Drug Ocrevus
by Zacks Equity Research
Roche (RHHBY) announced positive long-term data on leukemia drug Gazyva and MS drug Ocrevus.
Roche's (RHHBY) Avastin Gets Label Expansion Approval by FDA
by Zacks Equity Research
Roche (RHHBY) announced that the FDA has approved the label expansion for its oncology drug Avastin in combination with chemotherapy, for the treatment of women with advanced ovarian cancer following initial surgical resection.
Allergan (AGN) Presents Positive Data on Glaucoma Candidate
by Zacks Equity Research
Allergan (AGN) posts positive top-line data from a phase III study on Bimatoprost SR, a biodegradable implant for reducing IOP in patients with open-angle glaucoma or ocular hypertension.
Merck's Keytruda Gets FDA Nod for 2nd Lymphoma Indication
by Zacks Equity Research
Merck's (MRK) Keytruda gets FDA approval for primary mediastinal B-cell lymphoma (PMBCL) - its second label expansion approval this week.
Merck's (MRK) Keytruda Gets FDA Approval for Cervical Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda receives accelerated approval for the treatment of patients with advanced cervical cancer.